How NAION fits into the current semaglutide picture
The U.S. Wegovy label still talks about diabetic retinopathy complications in patients with type 2 diabetes. It does not use NAION as the main U.S. label term. That matters because retinopathy and NAION are not the same eye issue and should not be collapsed into one vague vision page.
At the same time, the current NAION discussion is no longer just internet speculation. EMA concluded in 2025 that NAION is a very rare side effect of semaglutide medicines and recommended updating product information. That makes NAION a distinct research and safety topic even if the U.S. label language is not framed the same way.
Why this became its own litigation track
On December 15, 2025, the JPML created MDL 3163 for GLP-1 NAION cases. The transfer order says those cases share factual questions about development, testing, regulatory history, labeling, and whether the products can cause NAION.
That court structure matters because it shows the federal litigation is no longer one giant bucket. The current GLP-1 mass-tort landscape separates severe GI claims from the more specific sudden-vision-loss and NAION track.
What the current research actually supports
The current ophthalmology literature is still evolving, but it is now specific enough that a serious site should acknowledge it directly. Recent JAMA Ophthalmology research examined semaglutide exposure and NAION rather than using only broad "vision loss" language.
That does not mean every sudden vision symptom on semaglutide is NAION, and it does not prove the same risk in every patient. It does mean a careful page should separate optic-nerve injury questions from diabetic retinopathy, blurry vision, or temporary visual changes.
What records matter most if sudden vision loss happened
The most useful records are usually ophthalmology or neuro-ophthalmology notes, visual-field testing, optic-nerve imaging, the exact date symptoms started, which eye was affected, the semaglutide product used, and whether the dose had recently changed.
If someone later needs a closer review, the timeline should also show prior diabetic eye history, prior vascular risk factors if known, and what the treating eye specialist called the condition. A general note saying only "vision issue" is much weaker than a specific diagnosis and exam history.